More Articles

South Africa introduces new patent policy Policies & Legislation | Posted 13/09/2013

South Africa has become the latest country to examine its patent laws with a view to curbing patent evergreening and increasing production of generics.

California Assembly passes biosimilars substitution bill Policies & Legislation | Posted 13/09/2013

California has taken a step closer to adopting legislation which would authorize pharmacists to substitute an FDA-approved biosimilars for their reference biologicals with a notification to prescri...

Actavis confirms Rayos patent challenge and Warner Chilcott acquisition Generics/News | Posted 13/09/2013

Actavis has filed for US approval for a generic version of the anti-inflammatory or immunosuppressive agent Rayos (prednisone). The company also confirmed its proposed acquisition of Warner Chilcott.

Celltrion applies for biosimilar infliximab approval in Japan Biosimilars/News | Posted 13/09/2013

On 11 September 2013, South Korean biotechnology company Celltrion announced that it had filed for approval of Remsima, its biosimilar infliximab monoclonal antibody, with Japan’s Ministry of Healt...

Ranbaxy to expand Russian portfolio Generics/News | Posted 13/09/2013

Generics manufacturer Ranbaxy Laboratories (Ranbaxy) has been in the Russian pharmaceuticals market for 20 years and is now considering expanding its product offering in the country.

India’s pharma moving from generics to niche drugs Reports | Posted 13/09/2013

Indian pharmaceutical companies will increasingly move away from the overcrowded and competitive area of generics and invest more R & D spending in niche drugs, according to a new report.

Akorn to buy Hi-Tech Pharmacal for US$640 million Pharma News | Posted 13/09/2013

Generic eye-drugmaker Akorn has entered into a deal to buy Hi-Tech Pharmacal (Hi-Tech) for US$640 million in cash to expand into oral liquids and ointments, including cold and cough treatments.

Therapeutic substitution could save Americans money Generics/Research | Posted 06/09/2013

Substituting more expensive brand-name drugs with generics or therapeutic substitutes, could lead to significant savings for Medicare Part D beneficiaries, according to US researchers [1].